HemoGenyx
HemoGenyx Pharmaceuticals is a London-headquartered, LSE-listed clinical-stage biopharma developing CAR-T cell therapy (HG-CT-1), bispecific antibodies, and immune-cell programming platforms to treat relapsed/refractory acute myeloid leukaemia, other blood diseases, and viral infections.
- Company typePublic
- Founded2013
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What HemoGenyx does
HemoGenyx Pharmaceuticals plc is a clinical-stage biopharmaceutical company developing cell and antibody therapies for blood cancers, autoimmune diseases, and viral infections. Its lead clinical asset is HG-CT-1 (HEMO-CAR-T), an autologous CAR-T cell therapy constructed using a proprietary humanised monoclonal antibody against the FLT3 receptor overexpressed on acute myeloid leukaemia (AML) cells; HG-CT-1 is currently in Phase I clinical trials for adult and pediatric (12-18) relapsed/refractory AML, with early data showing CAR-T expansion, blast reductions, and a manageable safety profile. The pipeline also includes CDX, a FLT3-targeting bispecific antibody licensed exclusively from Eli Lilly for AML treatment and bone-marrow transplant conditioning; CBR, a Chimeric Bait Receptor platform that programs myeloid immune cells against viruses (proof-of-concept for SARS-CoV-2) and certain cancers; Hu-PHEC cell therapy licensed from Cornell; and proprietary Advanced Hematopoietic Chimera (AHC) humanised mouse models used as a research and drug-discovery engine.
The company has no commercial products or licensing revenue; it operates as a pre-revenue R&D entity, funding operations entirely through periodic equity placings on UK public markets. The business model targets upfront payments, milestone payments, and royalties from out-licensing its therapies to larger pharmaceutical partners for commercialisation. Manufacturing has transitioned from in-house clean-room production at its Manhattanville, New York laboratory to CDMO Made Scientific (technology transfer completed March 2026), with a parallel early-commercialisation pathway being established in Estonia via Cellin Technologies OÜ under the hospital exemption route. The company is headquartered in London (UK company number 08401609), with R&D operations in New York through wholly-owned subsidiaries Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, and trades on the London Stock Exchange Main Market (LSE: HEMO) following its December 2025 admission.
HemoGenyx firmographics
Firmographics- Name
- HemoGenyx
- Legal name
- Hemogenyx Pharmaceuticals plc
- Website
- http://www.hemogenyx.com/
- Company type
- Public
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- HemoGenyx Pharmaceuticals is a London-headquartered, LSE-listed clinical-stage biopharma developing CAR-T cell therapy (HG-CT-1), bispecific antibodies, and immune-cell programming platforms to treat relapsed/refractory acute myeloid leukaemia, other blood diseases, and viral infections.
- Ownership category
- akta.pro rank
HemoGenyx industry classification
Industry- Product category
- Clinical-stage biopharmaceutical drug development
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
- akta.pro secondary industry
- Transplant & Immunosuppression Specialty Pharmaceuticals (HLAIACAJ)
Keywords
Where HemoGenyx is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
HemoGenyx business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Others
Revenue model
- Licensing and Royalty Revenue: Pre-revenue clinical-stage biopharmaceutical company. Business model aims to license therapies to partners for upfront payments, research funding, milestone payments, and royalty streams. Products have not yet reached commercialization.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
HemoGenyx product offering
Product offeringCore offering
Hemogenyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel cell therapies and immunotherapies for blood cancers (notably acute myeloid leukemia), viral infections, and autoimmune diseases. Its lead product candidate HEMO-CAR-T (HG-CT-1) is a CAR-T cell therapy in Phase I clinical trials for relapsed/refractory AML, while the pipeline also includes the CDX bi-specific antibody for AML treatment and transplant conditioning and the CBR (Chimeric Bait Receptor) immunotherapy platform. The company intends to commercialize its therapies through licensing to pharmaceutical partners, generating upfront, milestone, and royalty revenue.
Product overview
Hemogenyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of distinct and complementary products for blood and autoimmune diseases. The core product portfolio includes HEMO-CAR-T (HG-CT-1), a CAR-T cell therapy for Acute Myeloid Leukemia currently in Phase I clinical trials; CDX Bi-Specific Antibody for AML treatment and bone marrow transplant conditioning; and the CBR (Chimeric Bait Receptor) platform technology for targeting cancer and infectious diseases. The company also holds a license to the Hu-PHEC cell therapy approach and has developed Advanced Hematopoietic Chimeras (AHC) as proprietary research models. These products are at varying stages of development, with HEMO-CAR-T being the most advanced clinical program.
Differentiator
Problem solved
Functional benefit
Products and services
- HEMO-CAR-T (HG-CT-1) A CAR-T cell therapy that reprograms a patient's own T cells to recognize and destroy acute myeloid leukemia (AML) cells, using the company's proprietary humanized monoclonal antibody against the FLT3 protein overexpressed on AML blasts. Intended for adult and pediatric patients (aged 12-18) with relapsed/refractory AML who have failed or are refractory to standard treatments.
- CDX Bi-Specific Antibody A bi-specific antibody that redirects patients' own immune cells to eliminate FLT3+ AML cells and hematopoietic stem cells, intended for treatment of relapsed/refractory AML and for less toxic conditioning of patients undergoing bone marrow or hematopoietic stem cell transplantation. Developed in collaboration with Eli Lilly under an exclusive worldwide license.
- CBR (Chimeric Bait Receptor) Immunotherapy Platform A novel immunotherapy platform that programs or redirects myeloid immune cells (such as macrophages) using synthetic proteins to combat viral infections and certain types of cancer, with proof of concept demonstrated for SARS-CoV-2. The platform is modular and can be reconfigured to target a wide range of viruses, bacteria, and malignant cells.
Quantifiable outcome
- DSMB authorized progression to dose-expansion phase and pediatric arm opening for HG-CT-1 Phase I trial
- +2 more outcomes
Companies that use HemoGenyx
Customer profileSegments3 records
Ideal customer profiles2 records
HemoGenyx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
HemoGenyx partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- Prevail InfoWorksminorContract research organization (CRO) providing clinical services for upcoming Phase I clinical trial for CAR-T therapy targeting AML under contract with Prevail Partners investment arrangement.
- Eli Lilly & Co.coreDevelopment collaboration concluded in 2021 resulting in selection of CDX antibody clone ready for IND-enabling studies. In October 2021, Hemogenyx secured exclusive worldwide license for all applications to intellectual property developed by Lilly related to CDX bispecific antibody.
- University of PennsylvaniacoreMaster Translational Research Services Agreement entered January 2021 with Penn, world's leading experts in CAR-T therapies, to advance HEMO-CAR-T toward and through clinical trials. Intended outcome is clinical proof of concept for HEMO-CAR-T.
- Rockefeller UniversityminorResearch collaboration announced May 2018 to develop new lupus therapies using company's Advanced Hematopoietic Chimera (AHC) platform.
Scale indicators9 records
Recent moves11 records
Expansion highlights6 records
HemoGenyx competitors and assessment
Company assessmentDirect peers
- Caribou Biosciences: Clinical-stage biotech developing allogeneic CAR-T cell therapies for hematological malignancies including B-cell lymphoma; comparable as a peer clinical-stage CAR-T developer targeting blood cancers with a similar asset profile to HEMO-CAR-T.
- Allogene Therapeutics: Clinical-stage biotech developing allogeneic ("off-the-shelf") CAR-T therapies for hematological cancers; directly comparable to Hemogenyx as a peer CAR-T developer pursuing similar indications with similar modality.
- Precision Biosciences: Clinical-stage cell therapy company developing allogeneic CAR-T therapies for hematological malignancies, including AML; directly comparable as a peer in CAR-T for blood cancers.
- Cellectis: Clinical-stage biotech developing gene-edited allogeneic CAR-T cell therapies for hematological malignancies; directly comparable to Hemogenyx as a CAR-T platform peer.
- Fate Therapeutics: Clinical-stage biotech developing iPSC-derived NK and T-cell therapies for cancer and autoimmune diseases; directly comparable as a peer cell therapy developer with overlapping indications.
- Vor BioPharma: Clinical-stage biotech focused on hematopoietic stem cell engineering and AML therapies, including transplant conditioning; directly comparable as a peer addressing AML and bone marrow transplant conditioning.
- Jasper Therapeutics: Clinical-stage biotech developing novel conditioning agents and stem cell transplant therapies; directly comparable as a peer in hematopoietic stem cell transplant conditioning, overlapping with Hemogenyx's CDX program.
- Autolus Therapeutics: Clinical-stage biotech developing programmed T-cell therapies for hematological cancers; directly comparable as a peer CAR-T developer with similar modality and target indications.
Broad incumbents
- Bristol Myers Squibb: Large pharmaceutical company with multiple approved CAR-T therapies (Breyanzi, Abecma) and a broad hematology/oncology franchise; comparable as the dominant incumbent in CAR-T and blood cancer therapeutics against which Hemogenyx is competing.
- Gilead (Kite Pharma): Major CAR-T franchise (Yescarta, Tecartus) within Gilead Sciences targeting hematological malignancies; comparable as a broad incumbent defining the CAR-T competitive landscape Hemogenyx is entering.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
HemoGenyx social profiles
Digital presenceHemoGenyx financial estimates
Financial estimateRevenue estimate
Valuation estimate
HemoGenyx leadership team
Management profileNumber of profiles
Profiles6 records
HemoGenyx subsidiaries and ownership
Company hierarchySubsidiaries3 records
HemoGenyx funding detail
Funding detailFunding overview
Funding rounds18 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HemoGenyx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HemoGenyx
What does HemoGenyx do?
Hemogenyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel cell therapies and immunotherapies for blood cancers (notably acute myeloid leukemia), viral infections, and autoimmune diseases. Its lead product candidate HEMO-CAR-T (HG-CT-1) is a CAR-T cell therapy in Phase I clinical trials for relapsed/refractory AML, while the pipeline also includes the CDX bi-specific antibody for AML treatment and transplant conditioning and the CBR (Chimeric Bait Receptor) immunotherapy platform. The company intends to commercialize its therapies through licensing to pharmaceutical partners, generating upfront, milestone, and royalty revenue.
Is HemoGenyx a public or private company?
HemoGenyx is a public company. It is classified as public and is currently operating.
When was HemoGenyx founded?
HemoGenyx was founded in 2013. It employs 11 to 50 people.
Where is HemoGenyx based?
HemoGenyx is headquartered in London, United Kingdom, in the Europe region.
How does HemoGenyx make money?
One revenue line is on record: licensing and Royalty Revenue.
Who are HemoGenyx's main competitors?
Direct peers on record are Caribou Biosciences, Allogene Therapeutics, Precision Biosciences, Cellectis, Fate Therapeutics, Vor BioPharma, Jasper Therapeutics and Autolus Therapeutics. Broad incumbents are Bristol Myers Squibb and Gilead (Kite Pharma).
Does HemoGenyx have an API?
No public API is recorded for HemoGenyx.
What industry is HemoGenyx in?
HemoGenyx's product category is Clinical-stage biopharmaceutical drug development. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIACAJ, Transplant & Immunosuppression Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.